Hengrui Medicine: Reached a global strategic cooperation and licensing agreement with Roche.

Hengrui Pharmaceuticals announced that the company has reached a global strategic partnership and license agreement with Bristol-Myers Squibb Company to jointly promote 13 early-stage projects covering oncology, hematology, and immunology. According to the agreement, BMS will pay Hengrui up to $950 million in related payments, including a $600 million upfront payment, a first anniversary payment of $175 million, and a second conditional anniversary payment of $175 million in 2028. The potential total transaction value of the agreement could reach approximately $15.2 billion, including the exercise of joint development project selection rights, as well as the achievement of corresponding development, registration, and commercialization milestones for all projects.